Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 11/07/2024

    Presentation of the DKFZ Innovation Award and DKFZ Patient Expert Award

    The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/presentation-dkfz-innovation-award-and-dkfz-patient-expert-award
  • Press release - 02/07/2024

    DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier

    Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-spin-epignostix-raises-euro-43m-seed-round-commercialize-diagnostic-tumor-classifier
  • Press release - 01/04/2022

    FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer

    On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
  • PixelBiotech GmbH - 27/07/2021 Teaser_HuluFISH_7_color_med.jpg

    Searching for tracks with cytogenetics and AI

    The startup Pixelbiotech combines fluorescence techniques with artificial intelligence to detect DNA and RNA in medical samples. HuluFISH is the name of the method, which allows for countless applications - from detecting viral infections, such as COVID-19 or African swine fever virus, to the quality control of gene and immunotherapeutic procedures in cancer medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/searching-tracks-cytogenetics-and-ai
  • Press release - 20/12/2022

    Enzyme inhibition promotes bone formation and curbs the development of bone metastases

    In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-inhibition-promotes-bone-formation-and-curbs-development-bone-metastases
  • Press release - 20/01/2025

    PAMSARC: New study at the NCT Heidelberg links research and clinical action

    Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pamsarc-new-study-nct-heidelberg-links-research-and-clinical-action
  • Press release - 08/05/2025

    Childhood brain tumors develop early in highly specialized nerve cells

    Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers have now published their findings in the journal Nature. They analyzed the genetic changes of each individual cancer cell in tumor samples in order to reconstruct which genetic changes occur first during tumor development and when.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/childhood-brain-tumors-develop-early-highly-specialized-nerve-cells
  • Press release - 14/12/2022

    New drug for metastatic prostate cancer now also approved in Europe

    On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neues-medikament-gegen-metastasierten-prostatakrebs-nun-auch-europa-zugelassen
  • Press release - 08/01/2024

    Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor

    Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Dossier - 18/04/2016 An image of a nucleosome

    Epigenetics – heritable traits without changing the DNA sequence

    Epigenetics, i.e. the inheritance of traits that does not involve a change in the DNA sequence, was once a controversial subject that has since become a central focus of biological research. Epigenetic inheritance is now studied by numerous national and international research programmes. Many cellular regulatory and differentiation processes are controlled by epigenetic mechanisms that take place on different levels.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/epigenetics-heritable-traits-without-changing-the-dna-sequence
  • Press release - 16/11/2021

    Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation

    Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
  • Press release - 18/11/2021

    Overcoming resistance to treatment for breast, bowel, and pancreatic cancer

    As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
  • Press release - 24/01/2023

    What keeps the immune defense in brain tumors functional

    Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/was-die-abwehrzellen-hirntumoren-funktionsfaehig-haelt
  • Press release - 18/10/2023

    SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease

    Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
  • Press release - 21/09/2023

    Mutation-specific peptide vaccine against midline gliomas used in patients for the first time

    Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time
  • Press release - 29/11/2021

    Tracking down resistant cancer cells

    In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
  • Dossier - 05/11/2012 18550_de.jpg

    Cancer basic research successes and trends

    Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends
  • Press release - 14/03/2022

    Do gut bacteria influence treatment success of CAR-T cell therapies?

    Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
  • Press release - 16/06/2023

    What determines whether breast cancer cells can form metastases?

    In most cancers, it is not the growth of the primary tumor that determines the prognosis for the patient, but whether it will spread and form metastases. This process is very complex. There are often years between the development of the cancer and the aggressive growth of the metastases. Scientists from the DKFZ, the HI-STEM, the Ruhr University Bochum, Helmholtz Munich and ETH Zurich have studied and identified metastasis growth in breast cancer

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-determines-whether-breast-cancer-cells-can-form-metastases
  • Press release - 18/03/2025

    Maternal overweight as risk factor for childhood leukemia in daughters

    The weight of expectant mothers could play a role in the development of acute lymphoblastic leukemia (ALL) in daughters – but not in sons. This has been shown by researchers at the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/maternal-overweight-risk-factor-childhood-leukemia-daughters
  • Press release - 09/11/2022

    New Molecular Microscopy Uncovers how Breast Cancer Spreads

    Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
  • Press release - 21/09/2022

    ERC funding: How to deliver gene therapies to a specific target site?

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
  • Press release - 10/11/2023

    Therapy resistance in multiple myeloma: molecular analyses of individual cancer cells reveal new mechanisms

    All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapy-resistance-multiple-myeloma-molecular-analyses-individual-cancer-cells-reveal-new-mechanisms
  • Press release - 16/06/2025

    Novel laboratory models pave the way for targeted therapies for childhood sarcomas

    Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-laboratory-models-pave-way-targeted-therapies-childhood-sarcomas
  • Press release - 23/06/2022

    Cancer patients receiving immunotherapy: no evidence of increased risk for severe immune complication after COVID-19 vaccination

    Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-patients-receiving-immunotherapy-no-evidence-increased-risk-severe-immune-complication-after-covid-19-vaccination
  • Press release - 13/04/2022

    Emmy Noether funding for research into drug resistance of blood cancer

    The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/emmy-noether-funding-research-drug-resistance-blood-cancer
  • Press release - 07/02/2024

    The unexpected long-term consequences of female fertility

    The constant remodeling of the organs of the female reproductive tract during the reproductive cycle leads to fibrosis and chronic inflammation over the years. Scientists from the German Cancer Research Center (DKFZ) have now uncovered these unexpected long-term consequences of female reproductive function in mice. The results have been published in the scientific journal CELL.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/die-unerwartete-auswirkung-der-weiblichen-fortpflanzungsfaehigkeit
  • Press release - 15/11/2024

    Selenium proteins as a possible new target for cancer research

    An important enzyme helps the body produce selenium proteins – this discovery could open up new strategies for treating cancer in children. This has been published by scientists from the University of Würzburg, the University Sao Paolo, the German Cancer Research Center (DKFZ) and the Heidelberg Stem Cell Institute HI-STEM*.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/selenium-proteins-possible-new-target-cancer-research
  • Press release - 28/04/2022

    Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

    Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
  • Press release - 02/09/2021

    Award-winning science: Cancer-promoting metabolic pathways as targets of new therapies

    Christiane Opitz, scientist at the German Cancer Research Center, is being awarded this year's Ita Askonas Prize of the European Federation of Immunological Societies. Opitz has discovered how tumor cells use certain metabolites to protect themselves against the immune system. Her research findings may provide important clues for the development of new therapeutic concepts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-winning-science-cancer-promoting-metabolic-pathways-targets-new-therapies
  • Press release - 31/01/2024

    Precursor of Cholesterol Protects Cancer Cells From Cell Death and Makes them Aggressive

    A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cholesterin-vorstufe-schuetzt-krebszellen-vor-zelltod-und-macht-sie-aggressiver
  • Press release - 14/03/2024

    Machine learning classifier accelerates the development of cellular immunotherapies

    Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/machine-learning-classifier-accelerates-development-cellular-immunotherapies
  • Press release - 07/04/2025

    Physical training has a positive effect on the sexual health of women with metastatic breast cancer

    Metastatic breast cancer requires complex and lengthy treatment, the side effects of which affect the quality of life of patients. These often include sexual problems. In a large international randomized exercise intervention trial, researchers have now shown that women who received a nine-month supervised exercise program reported significantly fewer symptoms than women who did not participate in the training program.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/physical-training-has-positive-effect-sexual-health-women-metastatic-breast-cancer
  • Press release - 16/05/2023

    First company in the world to offer preclinical drug tests for children with cancer

    The recently established ITCC-P4 gGmbH provides academic institutions and pharmaceutical companies with a comprehensive repertoire of modern laboratory models of pediatric tumors. The aim is to systematically test new treatment options for children and adolescents with cancer and to contribute data to regulatory approval processes in order to make the development of new cancer therapies for children and adolescents more attractive.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-company-world-offer-preclinical-drug-tests-children-cancer
  • Press release - 18/12/2021

    WHO publishes first classification of childhood tumors

    The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/who-publishes-first-classification-childhood-tumors
  • Press release - 07/12/2021

    Moderate immune response is more effective against leukemia

    The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia
  • Press release - 13/05/2025

    Award for Outstanding Contributions to Cancer Research

    Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young researchers from the Heidelberg research location who have already drawn attention to themselves through the outstanding scientific quality of their cancer research.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-outstanding-contributions-cancer-research
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Press release - 14/08/2024

    New vaccine against cervical cancer combines prophylactic and therapeutic activities

    Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
  • Press release - 07/02/2025

    Multiple myeloma: When cancer cells break out of the bone marrow, a dangerous diversity arises

    A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-myeloma-when-cancer-cells-break-out-bone-marrow-dangerous-diversity-arises
  • Press release - 11/03/2025

    Frequent blood donations promote the regeneration of blood cells through genetic adaptation

    Donating blood saves lives – but what long-term effects does this practice have on our bodies? Researchers from the German Cancer Research Center (DKFZ), the HI-STEM stem cell institute* and the German Red Cross Blood Donor Service, among others, have now discovered that frequent blood donations cause genetic adaptations in blood stem cells that promote the regeneration of blood cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/frequent-blood-donations-promote-regeneration-blood-cells-through-genetic-adaptation
  • Press release - 03/04/2025

    Heinz Maier-Leibnitz Prize for Lukas Bunse

    Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heinz-maier-leibnitz-prize-lukas-bunse
  • Press release - 07/05/2024

    Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects

    Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
  • Press release - 17/02/2025

    Pancreatic cancer: blocked nerves as a possible new treatment strategy

    Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)*. The team discovered that the tumor reprograms the neurons for its own benefit.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-blocked-nerves-possible-new-treatment-strategy
  • Press release - 24/03/2021

    Vaccination against mutated protein tested in brain tumor patients for the first time

    Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-against-mutated-protein-tested-brain-tumor-patients-first-time
  • Press release - 15/11/2021

    Using T cell to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Press release - 24/02/2021

    Disease progression in childhood cancer: Lengthening of telomeres promotes relapse

    Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/disease-progression-childhood-cancer-lengthening-telomeres-promotes-relapse
  • Press release - 18/10/2021

    More precise characterization of brain tumors improves diagnosis and therapy

    An international study with about 3000 patients confirms the validity of a new classification system for meningiomas. It combines tissue characteristics (histology) with molecular analyses and thus improves therapy planning.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-characterization-brain-tumors-improves-diagnosis-and-therapy
  • Press release - 12/07/2023

    Mast cells as a sensor: Enigmatic immune cells help to avoid harmful allergens

    The function of mast cells, which are part of the immune system, is still a mystery. Scientists at the German Cancer Research Center (DKFZ) have now shown in mice: mast cells function as a sensor that signals the animals to avoid antigens, including harmful allergens, and thereby protect themselves from health-threatening inflammatory reactions. The findings were published in the journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mastzellen-als-sensor-raetselhafte-immunzellen-helfen-schaedliche-allergene-zu-vermeiden

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search